Journal for ImmunoTherapy of Cancer (Sep 2022)

Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI

  • Joe-Elie Salem,
  • Enriqueta Felip,
  • Shuchi Anand,
  • Karolina Benesova,
  • Marlies Ostermann,
  • Ala Abudayyeh,
  • Omar Mamlouk,
  • Umut Selamet,
  • Grace Cherry,
  • Sunandana Chandra,
  • Sandra M Herrmann,
  • Maria Jose Soler,
  • Abhijat Kitchlu,
  • Jamie S Lin,
  • Kerry L Reynolds,
  • Elizabeth M Gaughan,
  • Eva Muñoz-Couselo,
  • Jamie S Hirsch,
  • Pablo Garcia,
  • Meghan E Sise,
  • Thibaud Koessler,
  • Mark Eijgelsheim,
  • Shruti Gupta,
  • Frank B Cortazar,
  • Jason M Prosek,
  • Ilya Glezerman,
  • Shveta S Motwani,
  • Naoka Murakami,
  • Rimda Wanchoo,
  • David I Ortiz-Melo,
  • Arash Rashidi,
  • Ben Sprangers,
  • Vikram Aggarwal,
  • A Bilal Malik,
  • Sebastian Loew,
  • Christopher A Carlos,
  • Pazit Beckerman,
  • Zain Mithani,
  • Chintan V Shah,
  • Amanda D Renaghan,
  • Sophie De Seigneux,
  • Luca Campedel,
  • Daniel Sanghoon Shin,
  • Sunil Rangarajan,
  • Priya Deshpande,
  • Gaia Coppock,
  • Marium Husain,
  • Clara Garcia-Carro,
  • Sheila Bermejo,
  • Nuttha Lumlertgul,
  • Nina Seylanova,
  • Busra Isik,
  • Aydin Kaghazchi,
  • Yuriy Khanin,
  • Sheru K Kansal,
  • Kai M Schmidt-Ott,
  • Raymond K Hsu,
  • Maria C Tio,
  • Harkarandeep Singh,
  • Kenar D Jhaveri,
  • David E Leaf,
  • Corinne Isnard Bagnis,
  • Suraj S Mothi,
  • Weiting Chang,
  • Vipulbhai Sakhiya,
  • Daniel Stalbow,
  • Sylvia Wu,
  • Armando Cennamo,
  • Anne Rigg,
  • Nisha Shaunak,
  • Zoe A Kibbelaar,
  • Harish S Seethapathy,
  • Meghan Lee,
  • Ian A Strohbhen,
  • Ilya G Glezerman,
  • Dwight H Owen,
  • Sharon Mini,
  • Andrey Kisel,
  • Nicole Albert,
  • Katherine Carter,
  • Vicki Donley,
  • Tricia Young,
  • Heather Cigoi,
  • Els Wauters Ben Sprangers,
  • Javier A Pagan,
  • Jonathan J Hogan,
  • Valda Page,
  • Samuel AP Short,
  • A Bilal Malik,
  • Maria Josep Carreras,
  • Sethu M. Madhavan

DOI
https://doi.org/10.1136/jitc-2022-005646
Journal volume & issue
Vol. 10, no. 9

Abstract

Read online

Background Corticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause numerous adverse effects and may decrease progression-free survival among patients treated with ICPis. We sought to determine whether a shorter duration of corticosteroids was equally efficacious and safe as compared with a longer duration.Methods We used data from an international multicenter cohort study of patients diagnosed with ICPi-AKI from 29 centers across nine countries. We examined whether a shorter duration of corticosteroids (28 days or less) was associated with a higher rate of recurrent ICPi-AKI or death within 30 days following completion of corticosteroid treatment as compared with a longer duration (29–84 days).Results Of 165 patients treated with corticosteroids, 56 (34%) received a shorter duration of treatment and 109 (66%) received a longer duration. Patients in the shorter versus longer duration groups were similar with respect to baseline and ICPi-AKI characteristics. Five of 56 patients (8.9%) in the shorter duration group and 12 of 109 (11%) in the longer duration group developed recurrent ICPi-AKI or died (p=0.90). Nadir serum creatinine in the first 14, 28, and 90 days following completion of corticosteroid treatment was similar between groups (p=0.40, p=0.56, and p=0.89, respectively).Conclusion A shorter duration of corticosteroids (28 days or less) may be safe for patients with ICPi-AKI. However, the findings may be susceptible to unmeasured confounding and further research from randomized clinical trials is needed.